CHAIR
:
SPEAKER
(S):
Finley Austin, , Director , Roche
Jeffrey Elton, Senior Vice President of Strategy and Global Chief Operating Officer, Novartis Institutes for BioMedical Research
George Annas, Professor, Boston University School of Public Health
Bernd Kasemir, Founding Director, sustainserv, Inc.
Steven Holtzman, Chairman & Chief Executive Officer , Infinity Pharmaceuticals, Inc.
Simon Best, Chairperson, BioIndustry Association (UK)
Description
In this session, leading academic and industry leaders will discuss the what—if any—is the biotechnology industry's responsibility for human rights. Specific areas will include corporate sponsorship of human subjects research; access to and affordability of biotech products; whether biotech companies have heightened obligations because they are part of the human health-care enterprise; and the development of technologies that affect our definition(s) of what is "human."
Objectives:
Enhance biotechnology leaders' familiarity with the "human rights" paradigm that, increasingly, forms a basis for scrutiny of industrial practices.
Highlight specific industrial practices (e.g., research in developing countries) that can be the subject of humans rights–related inquiry.
Consider the similarities and differences among "corporate social responsibility," "sustainability," "bioethics" and "human rights" views of biotechnology.